Medexus Pharmaceuticals (TSE:MDP – Free Report) had its price objective increased by Stifel Nicolaus from C$4.15 to C$4.50 in a research report released on Tuesday morning,BayStreet.CA reports.

Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.